Gene · 4102
Papers3,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 3,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An Analysis of BMP1 Associated with m6A Modification and Immune Infiltration in Pancancer. | Dis Markers | 2022 | 36267461 | PubTator, text mining | PubMed |
| Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. | Adv Sci (Weinh) | 2022 | 36257824 | PubTator, text mining | PubMed |
| Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions. | Technol Cancer Res Treat | 2022 | 36254553 | PubTator, text mining | PubMed |
| Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. | J Immunother Cancer | 2022 | 36252996 | PubTator, text mining | PubMed |
| Drug repositioning for esophageal squamous cell carcinoma. | Front Genet | 2022 | 36246638 | PubTator, text mining | PubMed |
| Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines. | Polymers (Basel) | 2022 | 36236141 | PubTator, text mining | PubMed |
| Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents. | Molecules | 2022 | 36235168 | PubTator, text mining | PubMed |
| Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. | Int J Mol Sci | 2022 | 36232698 | PubTator, text mining | PubMed |
| Single-Cell Identification of Melanoma Biomarkers in Circulating Tumor Cells. | Cancers (Basel) | 2022 | 36230844 | PubTator, text mining | PubMed |
| Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle. | Cancers (Basel) | 2022 | 36230819 | PubTator, text mining | PubMed |
Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. | Front Pharmacol | 2022 | 36225561 | PubTator, text mining | PubMed |
| Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. | Front Immunol | 2022 | 36211378 | PubTator, text mining | PubMed |
| Identification and assessment of TCR-T cells targeting an epitope conserved in SARS-CoV-2 variants for the treatment of COVID-19. | Int Immunopharmacol | 2022 | 36201943 | PubTator, text mining | PubMed |
| A pan-cancer analysis of matrisome proteins reveals CTHRC1 and a related network as major ECM regulators across cancers. | PLoS One | 2022 | 36190948 | PubTator, text mining | PubMed |
| Dissecting novel mechanisms of hepatitis B virus related hepatocellular carcinoma using meta-analysis of public data. | World J Gastrointest Oncol | 2022 | 36187396 | PubTator, text mining | PubMed |
| Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. | Lancet Oncol | 2022 | 36174631 | PubTator, text mining | PubMed |
| High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity. | Immunity | 2022 | 36174557 | PubTator, text mining | PubMed |
| Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. | J Immunother Cancer | 2022 | 36171009 | PubTator, text mining | PubMed |
| Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC. | Cell Death Dis | 2022 | 36167821 | PubTator, text mining | PubMed |
| The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy. | J Exp Clin Cancer Res | 2022 | 36167539 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4102/papers?page=22